| Cover | Oct. 05, 2020 |
| Cover [Abstract] | |
| Document Type | 8-K |
| Amendment Flag | false |
| Document Period End Date | Oct. 5, 2020 |
| Entity File Number | 001-37418 |
| Entity Registrant Name | Axovant Gene Therapies Ltd. |
| Entity Central Index Key | 0001636050 |
| Entity Tax Identification Number | 98-1333697 |
| Entity Incorporation, State or Country Code | D0 |
| Entity Address, Address Line One | Suite 1, 3rd Floor |
| Entity Address, Address Line Two | 11-12 St. James’s Square |
| Entity Address, City or Town | London |
| Entity Address, Country | GB |
| Entity Address, Postal Zip Code | SW1Y 4LB |
| Country Region | 44 |
| City Area Code | 203 |
| Local Phone Number | 997 8931 |
| Written Communications | false |
| Soliciting Material | false |
| Pre-commencement Tender Offer | false |
| Pre-commencement Issuer Tender Offer | false |
| Title of 12(b) Security | Common Shares, $0.00001 par value per share |
| Trading Symbol | AXGT |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | true |
| Elected Not To Use the Extended Transition Period | true |
